louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04180839: Retrieval-extinction Paradigm on Internet Gaming Disorder
Official title: Reducing Gaming Cue Reactivity and Behavior Via Retrieval-Extinction Mechanism
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Internet Gaming Disorder
Lead sponsor: Beijing Normal University
Sponsor class: OTHER
First posted: 2019-11-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The overall aim of this experimental study is to apply the new paradigm of substance addiction intervention to the study of Internet gaming disorder(IGD) subjects' intervention.

Detailed description: This study is based on the retrieval-extinction paradigm.As with the efficacy, the experiment aims to test the effect of the retrieval-extinction paradigm on game craving and behave of IGD subjects, so as to provide an empirical basis for the development of effective intervention means of Internet gaming disorder.

Eligibility criteria: Inclusion Criteria:

1. the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5 ) recommended diagnosis of Internet gaming disorder : the scores of the 9 items of DSM-5 recommended diagnosis for Internet gaming disorder ≥ 5.
2. the scores of the Young-Internet addiction Test ≥ 50
3. engagement in popular Internet games (e.g. Arena of Valor, League of Legends and Player Unknown's Battle Grounds) for over 20 hours per week for a minimum of 12 months.

Exclusion Criteria:

1. current or history of use of illegal substances and other addictions;
2. current or history of psychiatric or neurological illness;
3. current use of psychotropic medications.

Primary outcomes:
measure: Mean Change in gaming craving at cue-reactivity task between the two test sessions
timeFrame: baseline , one day after training
Secondary outcomes:
measure: Mean Change in gaming Craving
timeFrame: The questionnaire is given to participants to record their gaming craving at baseline、after the first day of training、after the second day of training、one day after training、1 week and 1 month after tranning respectively
measure: Mean Change in gaming time at baseline、1-Week and 1-month Follow-Up
timeFrame: A diary is given to participants to record their gaming time at baseline、 1-week and 1-month
Other outcomes:
Locations:
city: Beijing
country: China
facility: State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University
state: Beijing
Study officials:
affiliation: Beijing Normal University
name: jintao Zhang, phD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Xue YX, Luo YX, Wu P, Shi HS, Xue LF, Chen C, Zhu WL, Ding ZB, Bao YP, Shi J, Epstein DH, Shaham Y, Lu L. A memory retrieval-extinction procedure to prevent drug craving and relapse. Science. 2012 Apr 13;336(6078):241-5. doi: 10.1126/science.1215070.
Clinical trial NCT01609439: Preoperative Vitamin D for Post-thyroidectomy Hypocalcemia
Official title: Pre-operative Vitamin D Supplementation to Reduce Post-operative Hypocalcemia in Patients Undergoing Total Thyroidectomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hypocalcemia
Keywords: Permanent
temporary
hypocalcemia
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2012-06-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if pre-operative vitamin D supplementation lowers the incidence of post-operative transient or permanent hypoparathyroidism in patients undergoing total thyroidectomy.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing total thyroidecomty +/- CND
* Adult (age \> or = 18)

Exclusion Criteria:

* Known chronic kidney disease
* Known primary hyper or hypoparathyroidism
* Known hypoalbuminemia
* Concurrent use medications affecting calcium metabolism
* Completion hemithyroidectomy

Primary outcomes:
measure: Hypocalcemia
timeFrame: Transient (<72 hrs post-operatively)
Secondary outcomes:
measure: Hypocalcemia
timeFrame: Permanent (>4 weeks)
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
References:
Clinical trial NCT01155739: Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
Official title: Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Secondary or Tertiary Peritonitis
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2010-07-02
Enrollment: 162
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: hospitalized patients with SIRS due to peritonitis or intra-abdominal infections

Brief summary: Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.

Detailed description: Prospective randomized trial

Eligibility criteria: Inclusion Criteria:

* More than 18 yo
* Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation...
* Mannheim Peritonitis score \> 14
* SIRS present
* Probability of survival \> 72h
* Informed consent by patient/relatives

Exclusion Criteria:

* No SIRS
* Long date corticoid treatment
* Immunosuppression
* Thyroid medullary carcinoma
* Anaphylactic shock
* Acute hepatic deficiency

Primary outcomes:
measure: antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost
timeFrame: at one month and during hospital stay
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: University Hospital of Lausanne
Study officials:
affiliation: Department of visceral surgery, university hospital
name: Steve Aellen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04670939: Respiratory Physiotherapy in Mechanical Ventilation
Official title: the Effect of Respiratory Physiotherapy to Weaning in Invasive Mechanical Ventilation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Failure
Keywords: respiratory physiotherapy
Lead sponsor: Muğla Sıtkı Koçman University
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to evaluate the effect of respiratory physiotherapy that is breathing exercise during weaning on ventilated patients in ICU.

Detailed description: Respiratory physiotherapy is a treatment approach to increase ventilation and function in patients with acute and chronic problems and to reduce respiratory work and dyspnea.Airway cleaning techniques, lung volume-enhancing approaches, thoracic mobilization, positioning, breathing exercises and inhalation therapy are among the strategies used.

In patients with invasive MV support, respiratory physiotherapy is the position, tracheal cleaning and inhalation therapy when necessary. But breathing exercises are not indicated in the acute phase. In the process of weaning, inspiratory muscle training and breathing exercises can be used.

Eligibility criteria: Inclusion Criteria:

* weaning period of patients in invasive mechanical ventilation
* patients in stable hemodynamic parameters

Exclusion Criteria:

* under 18 years old
* pregnant
* non-cooperative

Primary outcomes:
measure: weaning success
timeFrame: 1-7 days
Secondary outcomes:
measure: Compliance
timeFrame: 1-7 days
measure: diaphragmatic movement
timeFrame: 1-7 days
measure: arterial blood gas
timeFrame: 1-7 days
Other outcomes:
Locations:
city: Mugla
country: Turkey
facility: Mugla Sıtkı Kocman University Reasearch and Treaninig Hospital
Study officials:
affiliation: Muğla Sıtkı Koçaman University, Training And Research Hospital
name: Canan Gürsoy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00616239: Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
Official title: The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Melasma
Keywords: Melasma
Dark spots on the face
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
First posted: 2008-02-15
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will enroll 20 adult Hispanic women. Participants will apply 4% hydroquinone cream twice daily to affected areas on the face for 14 weeks and half the face will be peeled with 20-30% salicylic acid every two weeks for a total of 4 peels. The first two peels will be 20% salicylic acid and the second two peels will be with 30% salicylic acid. The purpose of the study will be to evaluate the safety and efficacy of salicylic acid combined with 4% hydroquinone versus 4% hydroquinone alone.


Eligibility criteria: Inclusion Criteria:

* Hispanic women ages 18-65 years of age with moderate to severe melasma
* English and Spanish-speaking women

Exclusion Criteria:

* Pregnant or breast-feeding women
* Subjects who have used 4% hydroquinone within 3 months of study start
* Subjects who have used chemical peels, microdermabrasion or facial laser treatments within 9 months of study start

Primary outcomes:
measure: Number of Participants Showing Improvement of Melasma Based on Mexameter Readings
timeFrame: 14 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials
state: Texas
Study officials:
affiliation: UT Southwestern Medical Center at Dallas - Department of Dermatology
name: Amit Pandya, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02466139: Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis
Official title: Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes Among Infective Endocaridtis Patients in a Tertiary-care Centre in Kerala
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infective Endocarditis
Keywords: microbiology
c reactive protein
urgent cardiac surgery
Lead sponsor: Government Medical College, Kozhikode
Sponsor class: OTHER
First posted: 2015-06-09
Enrollment: 102
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients with infective endocarditis treated in a tertiary care centre

Brief summary: The investigators conduct a prospective observational study on consecutive patients being admitted to a tertiary care-centre with infective endocarditis. The investigators' primary aim is to identify baseline clincal, laboratory and microbiological predictors of in-hospital events, mortality and 6-month mortality.

Detailed description: Mortality and major complications among infective endocarditis remain high. In addition developing nations are crippled with a high incidence of culture-negative endocarditis and lack of wide availability of transesophageal echocardiography. We intended to identify predictors among admission clinical features, laboratory paramters and culture reports that can help risk stratify patients early in the course of treatment.

Eligibility criteria: Inclusion Criteria:

* Fulfillment of modified Duke criteria

Exclusion Criteria:

* No consent
* inadequate baseline data

Primary outcomes:
measure: In-hospital mortality
timeFrame: 30 days
measure: Major complications
timeFrame: 30 days
Secondary outcomes:
measure: Number of patients who had embolic events
timeFrame: 30 days
measure: Number of patients who needed urgent cardiac surgery
timeFrame: 30 days
measure: Short term Mortality
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03421639: Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
Official title: A Controlled Trial on Adenomyosis Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus GnRH Analog Alone
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE4
Conditions: Uterine Adenomyosis
Recurrent Implantation Failure
Menstrual Pain
Keywords: Implantation failure
Adenomyosis
increased uterine size
IVF
egg donation cycle
Lead sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Sponsor class: NETWORK
First posted: 2018-02-05
Enrollment: 300
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial in two arms study (150 each one)
Primary purpose: TREATMENT

Brief summary: With this study the investigators want to test which is the best medical treatment for symptomatic adenomyosis affecting women undergoing IVF and with previous implantation failure, between Aromatase inhibitor plus GnRH analog versus GnRH alone, in term pregnancy rate and uterine volume reduction.

Detailed description: Recently it has been shown that adenomyosis negatively affects the pregnancy rate in IVF cycles. The investigators used in the past for the treatment of other benign gynecological diseases such as endometriosis and uterine myomas a combined therapy with Aromatase inhibitor plus GnRH analog. With this study the investigators want evaluate which is the best way to treat adenomyosis in order to obtain a higher pregnancy rate in women with symptomatic adenomyosis undergoing IVF who failed a previous IVF attempt. For these reasons the investigators set this controlled trial between GnRH analog plus Aromatase Inhibitor (3.75 mg monthly of Leuprolide plus 1.0mg day of Anastrazole for 3 months) versus an active comparator as GnRH analog alone (3.75 mg monthly of Leuprolide for 3 months) after the treatment patients will undergo embryo transfer of a cryopreserved blastocyst in a previous IVF cycle, and will be followed up for uterine dimension reduction and pain symptom reduction.

Eligibility criteria: Inclusion Criteria:

* women with healty conditions
* Adenomyosis
* increased uterine dimensions
* recurrent implantation failure

Exclusion Criteria:

* presence of systemic diseases

Primary outcomes:
measure: pregnancy after embryo transfer
timeFrame: 12 months
Secondary outcomes:
measure: uterine volume reduction
timeFrame: 12 months
Other outcomes:
Locations:
city: Tirana
country: Albania
facility: Spitali Amerikan
city: Sofia
country: Bulgaria
facility: Nadezda Women's Health Hospital
city: Rome
country: Italy
facility: Cerm-Hungaria
Study officials:
affiliation: CERM-HUNGARIA
name: MARCO SBRACIA, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02294539: Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients
Official title: Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controlled, Phase 4 Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Kyung Hee University Hospital at Gangdong
Sponsor class: OTHER
Collaborators: name: Hanmi Pharmaceutical Company Limited
First posted: 2014-11-19
Enrollment: 231
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate which combination therapy is more effective for improving the blood pressure (BP) and AM central SBP in hypertensive patients:Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) or ARB plus diuretics


Eligibility criteria: Inclusion Criteria:

* Hypertension patients not included exclusion criteria
* Mean seated SBP ≥140mmHg in patients with newly Diagnosed

Exclusion Criteria:

- msDBP≥110mmHg or ms SBP ≥ 180mmHg at the screening and randomization visit

Primary outcomes:
measure: change from baseline in msSBP
timeFrame: 4 weeks
Secondary outcomes:
measure: change from baseline in AMcSBP
timeFrame: 20 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital at Gangdong
Study officials:
affiliation: Kyung Hee University Hospital at Gangdong
name: Chong-Jin Kim
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cho EJ, Lee HY, Sung KC, Park S, Sohn IS, Park CG, Choi DJ, Ha JW, Ahn YK, Shin J, Hong SJ, Kim SK, Chung WJ, Yoo BS, Hong TJ, Youn HJ, Cho MC, Chae SC, Kim YJ, Kim CJ. Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study. Am J Hypertens. 2019 Sep 24;32(10):992-1002. doi: 10.1093/ajh/hpz050.
citation: Oh GC, Lee HY, Chung WJ, Youn HJ, Cho EJ, Sung KC, Chae SC, Yoo BS, Park CG, Hong SJ, Kim YK, Hong TJ, Choi DJ, Hyun MS, Ha JW, Kim YJ, Ahn Y, Cho MC, Kim SG, Shin J, Park S, Sohn IS, Kim CJ. Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial. Clin Hypertens. 2017 Sep 4;23:18. doi: 10.1186/s40885-017-0074-0. eCollection 2017.
Clinical trial NCT02844686: Myocardial Flow Reserve and 99mTc-DTPA Cardiac Dynamic SPECT
Official title: Feasibility of Dynamic Cardiac SPECT With 99mTc-diethylenetriaminepenta-acetate (DTPA) for the Assessment of Myocardial Flow Reserve Using a Cadmium-Zinc-Telluride (CZT) Camera
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Artery Disease
Keywords: Myocardial perfusion imaging
Single-Photon Emission Computer-Assisted Tomography
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2016-07-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: New CZT-based SPECT cameras are potentially capable of dynamic 3-D acquisition. Preliminary results suggested that dynamic acquisitions could allow the assessment of myocardial flow reserve using 99mTc-labelled perfusion tracers. The Flow-Heart study will assess the feasibility of myocardial flow reserve measurement by means of 99mTc-DTPA dynamic cardiac SPECT in 20 patients.


Eligibility criteria: Inclusion Criteria:

* Age over 18 years
* Patient clinically stable with known or suspected coronary disease
* Patient referred to Caen University Hospital for a myocardial perfusion SPECT
* Patient who accept to undergo subsequent additional cardiac dynamic SPECT using 99mTc-DTPA at rest and during pharmacological stress
* Informed consent dated and signed
* Affiliation to a social security system

Exclusion Criteria:

* Contraindication to dipyridamole (asthma, chronic obstructive pulmonary disease , pulmonary hypertension)
* History of poor tolerance of dipyridamole injection
* Cardiac arrhythmia (atrial fibrillation or frequent premature ventricular complex)
* Left bundle branch block, cardiac pacemaker, or implantable automatic defibrillator
* Recent history of myocardial infarction or unstable angina
* Pregnancy or lactating women
* Known obstructive renal or urinary disease
* Age under 18 years or guardianship
* Patient with an acute coronary syndrome or a coronary revascularization occurring between the conventional perfusion SPECT and the subsequent 99mTc-DTPA dynamic SPECT

Primary outcomes:
measure: Feasibility of myocardial flow reserve assessment by dynamic cardiac SPECT using a CZT camera and 99mTc-DTPA
timeFrame: Within one month after a conventional myocardial perfusion SPECT
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Caen
name: Alain Manrique, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: